ENSC Ensysce Biosciences, Inc.: יחס שווי כולל של החברה להכנסות

Ensysce Biosciences operates within a secure US legal framework, which mitigates external risks. The proprietary PFAB and MPAR systems allow the company to flexibly manage pricing within the safe analgesics niche. The EV/Sales multiple currently stands at -3659.13, which helps assess the business value relative to revenue. This results in the creation of a closed patent perimeter that ties clinics to unique drug activation protocols.
ensysce.com - פילוחים אנליטיים ומדדי מפתח (ENSC)

For Ensysce Biosciences (ENSC), which develops innovative overdose-protected analgesics, the current EV/Sales ratio reflects the enterprise value of the business net of debt relative to annual revenue. This metric measures the value of operating assets regardless of the financing structure, allowing investors to determine whether they are overpaying for the potential of technology commercialization or to identify an undervaluation of capital.